

News Release

Date: 28 January 2008

Bespak aids the development of three new products for Beximco

Products developed using Bespak's Metered Dose Inhaler (MDI) optimisation services have recently been launched in Bangladesh by Beximco Pharmaceuticals Ltd.

All three products; Azmasol[®] HFA, Decomit[®] 50 HFA and Decomit[®] 100 HFA, employ a Bespak valve and actuator and are aimed at patients with respiratory illnesses such as asthma. Azmasol, as a reliever medication, uses a Salbutamol formulation, whereas both the Decomit products act as preventative medication, using a Beclometasone Dipropionate (BDP) formulation.

Through its rigorous optimisation service, Bespak offers unrivalled expertise in managing the complex relationship between valve, actuator, formulation and drug pack, providing an optimised device development process for existing, novel and conceptual devices.

Bespak Commercial Director, Jay Bhogaita commented: "At Bespak we understand the importance of successfully pairing a drug with its delivery device and how fundamental this is in the safety and efficacy of the product and ultimately its commercial success. By utilising the expertise and skills of our scientists we are able to develop individual formulation and device designs much faster than through a trial and error approach."

Beximco Chief Executive Officer, Nazmul Hassan added: "Bespak's unique knowledge in working with valves, actuators and formulations was critical in enabling us to market HFA Azmasol[®] and Decomit[®]. With Bespak's help Beximco have been able to develop and market these MDI products quickly and efficiently. By sharing the development with Bespak's development team we've been able to take advantage of their unique understanding and the experience of some of the industry's leading MDI specialist engineers."

Bespak's breadth of expertise, coupled with its state-of-the-art facilities and core capabilities which include: formulation, laboratory-scale manufacture, pharmaceutical performance testing and device optimisation.

Ends

28 January 2008

About Consort Medical

Consort Medical plc develops drug delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings in hospitals. The Group has facilities in King's Lynn and Milton Keynes in the UK, Indianapolis, Indiana and Kent, Ohio in the US, and Mumbai, India. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CRST). For more information, please visit www.consortmedical.com

About Bepak

Bepak is a Consort Medical company that develops and manufactures metered dose inhaler valves, actuators, compliance aids and dry powder devices. Bepak also provides leading pharmaceutical and healthcare companies with a range of device manufacturing services including product development, industrialisation and contract manufacture. www.bepak.com

For further information please contact:

Chris Halling, Head of Corporate Communications.

Tel +44 (0) 1908 525201 or email chris.halling@consortmedical.com

For press information contact:

Paul Williamson, Realia

Tel +44 (0) 1227 731210 or email paul.williamson@realia-marketing.com

Kelly Cocks, Realia

Tel +44 (0) 1227 731210 or email kelly.cocks@realia-marketing.com